Brind.

BioPharma received a milestone payment for the Vitargus(R) licensing deal from ForSeeCon Eye Corporation.

1 report, 1 independent Updated Aug 22

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

BioPharma

Keep exploring

The entities involved

BioPharma
company in Jílové u Prahy, Czech Republic
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.Mon 02:47

Coverage

Newest first; wire copies grouped

Aug 22NewMediaWireABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal SILICON VALLEY, CA - August 22, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (